ABVC BioPharma (ABVC) Stock: Buy, Sell, or Hold?
ABVC - ABVC BioPharma, Inc. Common Stock
$1.01
-0.01 (-0.98%)
▼
5d:
-10.62%
30d:
+16.83%
90d:
-46.84%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 30, 2026
25d
Get Alerted When ABVC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABVC is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABVC is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABVC is currently trading at $1.01, which is considered fair relative to its 30-day fair value range of $0.89 to $1.13.
Technical Outlook: Technically, ABVC is in a downtrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABVC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.02 (+100.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABVC is in a downtrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABVC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.02 (+100.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.89 -
$1.13
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 100.0% below Wall St target ($2.02)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.89 -
$1.13
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.23
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Wall Street Target
$2.02
(+100.0%)
Revenue Growth (YoY)
104.5%
Share & Embed Analysis
Last updated: October 04, 2026 9:21 AM ET
Data refreshes hourly during market hours. Next update: 10:21 AM
Data refreshes hourly during market hours. Next update: 10:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABVC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$294 | 67 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
19 analysts |
$644 | 67 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
27 analysts |
$853 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$32 | 62 BUY |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
13 analysts |
$74 | 66 BUY |
